Regulatory
FDA Approves Tudriqev, an Engineered Cancer-Killing Virus for Advanced Melanoma
Replimune’s oncolytic virus, given with nivolumab, won accelerated approval for melanoma that has progressed on immunotherapy — after two prior rejections.